Back to today’s briefing

Story perspectives

FDA-Approved HIV Drugs Show Promise Against Alzheimer’s Risk

6/6/2025

42 10

Summary

Story summary

In a groundbreaking discovery, researchers at Sanford Burnham Prebys revealed that FDA-approved HIV drugs, designed to target reverse transcriptase (RT), might also reduce Alzheimer’s risk. They identified surprising RT activity in neurons, especially in Alzheimer’s-affected brains, opening the door for these existing drugs to be repurposed in clinical trials aimed at slowing the disease's progression.

1 of 1

Story summary

In a groundbreaking discovery, researchers at Sanford Burnham Prebys revealed that FDA-approved HIV drugs, designed to target reverse transcriptase (RT), might also reduce Alzheimer’s risk. They identified surprising RT activity in neurons, especially in Alzheimer’s-affected brains, opening the door for these existing drugs to be repurposed in clinical trials aimed at slowing the disease's progression.